These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31881458)

  • 1. Promiscuity analysis of a kinase panel screen with designated p38 alpha inhibitors.
    González-Medina M; Miljković F; Haase GS; Drueckes P; Trappe J; Laufer S; Bajorath J
    Eur J Med Chem; 2020 Feb; 187():112004. PubMed ID: 31881458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent p38α MAPK inhibitors through a funnel like workflow combining in silico screening and in vitro validation.
    Astolfi A; Kudolo M; Brea J; Manni G; Manfroni G; Palazzotti D; Sabatini S; Cecchetti F; Felicetti T; Cannalire R; Massari S; Tabarrini O; Loza MI; Fallarino F; Cecchetti V; Laufer SA; Barreca ML
    Eur J Med Chem; 2019 Nov; 182():111624. PubMed ID: 31445234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
    Goettert M; Schattel V; Koch P; Merfort I; Laufer S
    Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
    Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
    Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
    Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
    J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p38α MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening.
    Astolfi A; Iraci N; Sabatini S; Barreca ML; Cecchetti V
    Molecules; 2015 Aug; 20(9):15842-61. PubMed ID: 26334265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.
    Miljković F; Vogt M; Bajorath J
    J Comput Aided Mol Des; 2019 Jun; 33(6):559-572. PubMed ID: 30915709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
    Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
    Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
    Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
    Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
    Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds.
    Kong TT; Zhang CM; Liu ZP
    Curr Med Chem; 2013; 20(15):1997-2016. PubMed ID: 23317165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
    Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
    Swann SL; Merta PJ; Kifle L; Groebe D; Sarris K; Hajduk PJ; Sun C
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5787-92. PubMed ID: 20471255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
    Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
    Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.
    Miljković F; Bajorath J
    J Comput Aided Mol Des; 2020 Jan; 34(1):1-10. PubMed ID: 31792884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
    Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
    J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors.
    Astolfi A; Iraci N; Manfroni G; Barreca ML; Cecchetti V
    ChemMedChem; 2015 Jun; 10(6):957-69. PubMed ID: 26012502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
    Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
    Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2.
    Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5979-83. PubMed ID: 22901390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.